表紙
市場調査レポート

Advair(ぜんそく):市場の予測と分析

Advair (Asthma) - Forecast and Market Analysis to 2023

発行 GlobalData 商品コード 316073
出版日 ページ情報 英文 53 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.12円で換算しております。
Back to Top
Advair(ぜんそく):市場の予測と分析 Advair (Asthma) - Forecast and Market Analysis to 2023
出版日: 2014年08月31日 ページ情報: 英文 53 Pages
概要

AdvairはGSKにより開発された、プロピオン酸フルチカゾンおよびキシナホ酸サルメテロールのFDC(多剤混合薬)です。プロピオン酸フルチカゾンは強力な消炎作用のある合成コルチコステロイドです。フルチカゾンはグルココルチコイド受容体と高い親和性で結合し、ぜんそくに関連する媒介物(ヒスタミン、エイコサノイド、ロイコトリエン、サイトカインなど)の分泌を押さえる効果があります。ブデノシドよりも3倍の、またジプロピオン酸ベクロメタゾンの活性代謝物よりも2倍の効能を有しています。一方、キシナホ酸サルメテロールは高度に選択的なLABA(長時間作用性β2刺激薬)となっています。

当レポートでは、ぜんそくの治療薬の一つ、Advairの世界市場について分析し、ぜんそくの概要や治療法、競合する企業・薬品の概要、市場競争の概況、Advairの商品情報(特色・効能・安全性など)、世界の主要国における市場販売額の見通し(今後10年間分)などを調査して、その結果を概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

  • 分析の背景事情
  • 関連報告
  • 公開予定の関連報告書

第3章 疾患の概要

  • 病因と病態生理学
    • 病因
    • 病態生理学
    • 予後
    • 生活の質(QoL)
  • 症状

第4章 疾患管理

  • 診断および治療概要
    • 診断
    • 治療ガイドライン、臨床診療および代表的な処方薬
    • 臨床診療

第5章 競合評価

  • 概要
  • 戦略的競合評価

第6章 Advair(プロピオン酸フルチカゾン/キシナホ酸サルメテロール)

  • 概要
  • 有効性
  • 安全性
  • SWOT分析
  • 予測

第7章 付録

図表一覧

目次

GlobalData has released its new PharmaPoint Drug Evaluation report, "Advair (Asthma) - Forecast and Market Analysis to 2023". The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

Advair is an FDC of fluticasone propionate and salmeterol xinafoate developed by GSK. Fluticasone propionate is a synthetic corticosteroid with strong anti-inflammatory activity. Fluticasone can bind to glucocorticoid receptors with high affinity and inhibit the secretion of mediators involved in asthma, such as histamine, eicosanoids, leukotrienes, and cytokines. It is three times more potent than budenoside, and two times more potent than the active metabolite of beclomethasone dipropionate. Salmeterol xinafoate is a highly selective LABA.

Scope

  • Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Advair including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Advair for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Asthma
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Advair performance
  • Obtain sales forecast for Advair from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Advair (fluticasone propionate/salmeterol xinafoate)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed Asthma Patients
    • 7.4.2. Percent Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
    • 7.4.5. Generic Erosion
  • 7.5. Physicians and Specialists Included in This Study
  • 7.6. About the Authors
    • 7.6.1. Author
    • 7.6.2. Author/Reviewer
    • 7.6.3. Reviewer
    • 7.6.4. Global Head of Healthcare
  • 7.7. About GlobalData
  • 7.8. Disclaimer

List of Tables

  • Table 1: Symptoms of Asthma
  • Table 2: Treatment Guidelines for Asthma by Country
  • Table 3: Most Prescribed Drugs for Asthma by Class and Disease Severity in the Global Markets, 2013
  • Table 4: Dosing of Common ICSs for Adult Asthma Therapy to Achieve Equivalent Therapeutic Potency
  • Table 5: Recommended Low Daily Dose of ICSs in Children with Asthma Under Five Years of Age
  • Table 6: Leading Treatments for Asthma, 2014
  • Table 7: Product Profile - Advair
  • Table 8: Efficacy - Advair Diskus Versus Its Individual Components
  • Table 9: Advair, Frequency of Drug-Related Adverse Events
  • Table 10: Advair SWOT Analysis, 2014
  • Table 11: Global Sales Forecast ($) for Advair, 2013-2023
  • Table 12: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1:Stepwise Disease Management Approach for Asthma in Adults
  • Figure 2: Stepwise Disease Management Approach for Asthma in Children Age Five and Younger
Back to Top